HEM News Briefs

Novel Therapy Prevents Inhibitor in Hemophilia A Patients Receiving Recombinant FVIII Treatment

A tolerogenic form of factor VIII (FVIII) is useful as an immunotherapy strategy to prevent inhibitor development in patients with hemophilia A, according to a study published in the Journal of Thrombosis and Haemostasis.  Recombinant FVIII is the first-line treatment for patients with hemophilia A. However, the development of inhibitors is a serious complication because…

Case Report: An Unusual Clinical Presentation of Acquired Hemophilia A

Sokołowska et al reported the rare case of a 57-year-old man diagnosed with acquired hemophilia (AH) whose first clinical manifestations were epileptic seizure and hemorrhage into the ventricular system of the brain. This unusual case was recently published in the Annals of Agricultural and Environmental Medicine. The patient had a history of cerebral infarction, alcoholism,…

hemophilia etiology

Many Hemophilia Carriers Have Abnormal Bleeding Scores

Although the majority of hemophilia carriers have a normal bleeding score, a substantial proportion does not, according to a new study published in Haemophilia. “We believe this analysis contributes significantly to our understanding of bleeding symptoms in hemophilia carriers,” the authors of the study wrote, adding that it also identified the gaps in knowledge that…

Hemophilia A

Nanoparticle-Based Approach Shows Potential in Hemophilia

Researchers developed a nanoparticle platform for a novel lipid-based immunotherapy that aims to prevent undesirable immune responses against therapeutic proteins, such as the recombinant factor VIII (FVIII) in patients with hemophilia type A (HA). “In the case of HA, a bleeding disorder, about one third of the severe HA patients receiving replacement therapy using recombinant…

Hemophilia Symptoms

Clinicians Comfortable With Extended Half-Life Factor Products for Hemophilia

Clinicians are generally comfortable with using extended half-life factor products in patients with hemophilia for the same indications as those for standard half-life concentrates, including nonsevere hemophilia and previously untreated patients. This is according to a national survey of hemophilia providers from hemophilia treatment centers in the United States.  The results of the survey also…

Hemophilia A

Long-Term Exposure to Prophylactic Drug for Hemophilia A Improves Clinical Outcomes

Researchers have discovered that long-term exposure (>5 years) to the drug turoctocog alfa pegol (N8-GP) resulted in a hemostatic protective effect in patients with severe hemophilia A, according to a study published in Haemophilia. N8-GP has an extended half-life (EHL) recombinant factor VIII (FVIII) for the purpose of prophylaxis in patients with severe hemophilia A.…

The Etiology of AATD

Hemophilia Does Not Increase Risk of HCC After Hepatitis C Virus Eradication

Japanese researchers discovered that hepatitis C virus (HCV) infection in hemophilia did not increase the risk of hepatocellular carcinoma (HCC) if direct-acting antivirals facilitating a high rate of sustained virological response were administered, according to a study published in the Annals of Hepatology. Furthermore, the eradication of HCV could, in fact, decrease liver-related diseases in…

Researchers worked to better understand and manage patients with mild or moderate hemophilia, who can be an underrepresented and underserved population.

Consensus Statements Released for Pain Management in Hemophilia Patients

A group of Italian physicians has released new consensus statements on the assessment and management of adults and children with hemophilia. They were published in Blood Reviews. The statements were developed by the HAEMODOL study group through a Delphi consensus process that incorporated the expert opinions of 51 clinicians. “Ongoing monitoring and assessment of pain…

hemophilia comorbidities

Study Suggests Hemophilia A Could Be Treated With a Patient’s Own Cells

Researchers discovered that certain types of a patient’s own cells were viable candidates for delivering a long-lasting factor VIII transgene to treat hemophilia A, according to a news release on a study published in the Frontiers in Cell and Developmental Biology. The cell types investigated were mesenchymal stromal cells from amniotic fluid, the umbilical cord,…

Next post in HEM News Briefs